factor

(redirected from factor IX)
Also found in: Dictionary, Thesaurus, Medical, Financial, Encyclopedia, Wikipedia.
Related to factor IX: factor XI

Factor

An event, circumstance, influence, or element that plays a part in bringing about a result.

A factor in a case contributes to its causation or outcome. In the area of Negligence law, the factors, or chain of causation, are important in determining whether liability ensues from a particular action done by the defendant.

factor

n. 1) a salesman who sells in his/her own name on behalf of others, taking a commission for services. 2) something that contributes to the result.

factor

(Commission merchant), noun agent, broker, commercial agent, delegate, deputy, envoy, interagent, manager, medium, middleman, one who sells for factorage, proctor, procurator, representative
Associated concepts: consignee, factors' lien

factor

(Ingredient), noun additive, agent, aid, aspect, cause, component, constituent, constitutive element, content, contributing force, determinant, element, elementary unit, feature, integral part, part, portion, segment, unit
See also: aspect, broker, cause, characteristic, component, constituent, dealer, deputy, determinant, element, feature, ingredient, member, part, plenipotentiary, portion, procurator, reason, represent, substitute

factor

1 a mercantile agent. An agent who is in the ordinary course of business entrusted with goods or documents of title representing goods with a view to their sale. A factor has a lien over goods entrusted to him; this lien covers any claims he may have against his principal arising out of the agency. Most factors will be mercantile agents (and have the powers of such) for the purposes of the Factors Act 1889. Under this Act, in certain circumstances a factor may pass a good title to goods entrusted to him.
2 an institution to whom a company assigns its book debts (see FACTORING).
3 in Scotland a landlord or superior's agent.
References in periodicals archive ?
CSL Behring, with the help of its parent, is developing rIX-FP for the prophylaxis and treatment of bleeds in patients with congenital Factor IX (FIX) deficiency as part of the PROLONG-9FP clinical study programme.
Global biopharmaceutical group Ipsen (Paris:IPN.pa) (Euronext:IPN) announced today that its partner, Inspiration Biopharmaceuticals Inc, presented pharmacokinetic (PK) data on its lead product, IB1001, a recombinant factor IX (FIX) for the treatment and prevention of bleeding in individuals with haemophilia B.
Human factor ix concentrate, dust and solution for use parenteral 500 iu vial 5ml
The firm said it is preparing for additional clinical development work to establish safety, tolerability and proof-of-concept with a factor IX gene therapy produced using its proprietary AAV production system.
This haemophilia B gene therapy, administered once, will introduce the functional gene for the Factor IX protein into the patient's liver cells with the goal of restoring blood clotting functionality long-term.
The company said, "Earlier this month, the Company presented updated clinical data at the 2019 ISTH conference demonstrating that a single administration of AMT-061 resulted in sustained increases in Factor IX levels up to 54% of normal, with a mean for the three patients in the Phase IIb study of 45% of normal at 36 weeks post administration.
In haemophilia A, which represents 80-85% of cases, defects occur in the gene responsible for the production of a protein called factor VIII (FVIII), whereas the defect in haemophilia B affects factor IX (FIX) production, though the two conditions are clinically indistinguishable.
Summary: Injection of coagulation factor IX is the primary and widely adopted treatment option across the globe, which is further boosting the growth of global coagulation factor IX market.
[UKPRwire, Sun Jul 07 2019] Coagulation factor IX isn't made by the body of hemophilia B patient thereby, external injection of coagulation factor IX is necessary for the treatment of such disorder.
[USPRwire, Thu May 09 2019] Coagulation factor IX isn't made by the body of hemophilia B patient thereby, external injection of coagulation factor IX is necessary for the treatment of such disorder.
(NYSE: PFE) has initiated a Phase 3 open-label, multi-center, lead-in study to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in the usual care setting, the company and its development partner Philadelphia, Pennsylvania-based gene therapies specialist Spark Therapeutics (NASDAQ: ONCE) said.
Hemophilia B is a congenital bleeding disorder characterised by deficient or defective factor IX; nearly all affected patients are male.